吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2023 年 1 月 30 日召开第七届董事会第十五次会议、第七届监事会第十三次会议，并于 2023 年 2 月 15 日召开 2023 年第一次临时股东大会审议通过了《关于使用部分闲置募 集资金及自有资金进行现金管理的议案》，同意公司在确保公司募集资金投资项 目建设正常进行和资金安全的前提下，使用额度不超过人民币 2.8 亿元的部分闲 置募集资金（含超募资金）及额度不超过人民币 2.0 亿元自有资金进行现金管理， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可 循环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募 集资金及自有资金进行现金管理的公告》（公告编号：2023-004）。 上述现金管理情况详见公司在巨潮资讯网披露的《关于使用部分闲置募集资 金进行现金管理到期赎回并继续进行现金管理的进展公告》（公告编号：2023- 签约机构 产品名称 产品类型 金额 （万元） 产品起 息日 产品到 期日 年化 收益 率 赎回本金 （万元） ...

吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2023 年 1 月 30 日召开第七届董事会第十五次会议、第七届监事会第十三次会议，并于 2023 年 2 月 15 日召开 2023 年第一次临时股东大会审议通过了《关于使用部分闲置募 集资金及自有资金进行现金管理的议案》，同意公司在确保公司募集资金投资项 目建设正常进行和资金安全的前提下，使用额度不超过人民币 2.8 亿元的部分闲 置募集资金（含超募资金）及额度不超过人民币 2.0 亿元自有资金进行现金管理， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可 循环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募 集资金及自有资金进行现金管理的公告》（公告编号：2023-004）。 近日，公司使用部分闲置募集资金进行现金管理的产品已到期赎回，现就具 体情况公告如下： 证券代码：301130 证券简称：西点药业 公告编号：2023-065 吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回的进展公告 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 56,408,922.96, a decrease of 16.54% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 10,970,738.79, down 3.63% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 8,001,762.19, a decline of 12.40% compared to the previous year[5]. - Total revenue for the third quarter was CNY 170,495,925.88, a decrease of 7.4% compared to CNY 184,214,108.46 in the same period last year[22]. - Total operating costs amounted to CNY 143,337,161.46, down 4.0% from CNY 149,349,990.25 year-over-year[22]. - The net profit for Q3 2023 was CNY 41,294,028.25, representing a 28.6% increase compared to CNY 32,119,674.46 in Q3 2022[23]. - Basic and diluted earnings per share increased to CNY 0.5110 from CNY 0.4209, reflecting a growth of 21.5% year-over-year[24]. - Operating profit for the quarter was CNY 47,960,575.65, up 20.5% from CNY 39,612,741.18 in the same period last year[23]. - The total profit for the quarter was CNY 47,813,334.86, which is a 24.0% increase from CNY 38,585,579.35 in the same quarter last year[23]. - The company reported a decrease in cash received from sales of goods and services to CNY 195,456,109.30 from CNY 211,880,575.91, a decline of 7.7% year-over-year[24]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was CNY 31,132,671.06, representing a significant decrease of 37.07%[8]. - Cash flow from operating activities generated a net amount of CNY 31,132,671.06, down 37.1% from CNY 49,472,777.42 in Q3 2022[25]. - The total cash and cash equivalents at the end of the period stood at CNY 231,445,127.20, compared to CNY 189,575,322.78 at the end of Q3 2022, marking an increase of 22.1%[25]. - Cash and cash equivalents increased to CNY 232,005,069.60 from CNY 202,779,648.02 at the start of the year, representing a growth of 14.3%[20]. - The net cash flow from investment activities was CNY 11,020,283.95, a turnaround from a negative CNY 389,299,803.05 in Q3 2022[25]. - The total cash inflow from investment activities was CNY 1,019,259,001.30, significantly higher than CNY 498,783,198.62 in the previous year[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,194[10]. - The top ten unrestricted shareholders hold a total of 22,850,809 shares, with the largest shareholder, Dingdian Investment Management, holding 7,639,054 shares[14]. - The company’s major shareholder, Guotou High-Tech Investment Co., Ltd., holds 5,118,797 shares[14]. - The company’s stockholder, Shi Shilin, holds a total of 1,488,254 shares, with part held through a margin trading account[14]. - The company has a consistent action relationship among major shareholders, including Dingdian Investment and Guohongsheng[14]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,029,265,543.50, an increase of 1.21% from the end of the previous year[5]. - The company's total assets as of September 30, 2023, were CNY 1,029,265,543.50, up from CNY 1,017,003,454.64 at the beginning of the year[20]. - The total liabilities decreased to CNY 55,610,519.80 from CNY 71,713,828.31, a reduction of 22.5%[21]. - The company's equity attributable to shareholders rose to CNY 973,655,023.70, an increase of 3.0% from CNY 945,289,626.33[21]. - The equity attributable to shareholders at the end of the reporting period was CNY 973,655,023.70, up 3.00% from the previous year[5]. Research and Development - Research and development expenses increased to CNY 5,227,257.77, reflecting a rise of 27.7% compared to CNY 4,096,854.54 in the previous year[22]. Corporate Actions - The company established a wholly-owned subsidiary, Xidian (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., with a capital of RMB 20 million[16]. - The company held its second extraordinary general meeting on August 3, 2023, electing a new board of directors and supervisory board[15]. - The company has completed the registration procedures for its new subsidiary in Zhuhai, obtaining a business license[16]. - The company reported a total of 60,602,957 restricted shares, with 37,827,148 shares released during the period[14]. - The company’s restricted shares include those held by directors and senior management, with specific unlocking dates set[14]. - The company’s total number of restricted shares at the end of the period was 19,627,034, with no new restrictions added[13]. Miscellaneous - The company received government subsidies amounting to CNY 843,230.19 during the reporting period[6]. - The weighted average return on equity for the year-to-date was 4.29%, an increase of 0.49% compared to the previous year[5]. - The company did not undergo an audit for the Q3 report, which was released on October 25, 2023[26].

关于持股 5%以上的股东股份被司法冻结的公告 证券代码：301130 证券简称：西点药业 公告编号：2023-062 吉林省西点药业科技发展股份有限公司 一、股东股份被冻结基本情况 股东名称 是否为控股股东 或第一大股东及 其一致行动人 本次冻结 股份数量 （万股） 占其所 持股份 比例 占公司总 股本比例 是否为 限售股 起始日 到期日 冻结执行人 原因 横琴鼎典 否 763.9054 100% 9.45% 否 2023/09/ 19 2026/09/ 18 广东省珠海 市中级人民 法院 涉诉 合计 - 763.9054 100% 9.45% - - - - - 1、本次股份被冻结基本情况 2、股东股份累计被冻结情况 截至本公告披露日，横琴鼎典所持股份累计被冻结情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计被冻结数量 | 合计占其所 | 合计占公司 | | --- | --- | --- | --- | --- | --- | | | （万股） | | （万股） | 持股份比例 | 总股本比例 | | 横琴鼎典 | 763.9054 | 9.45% | 763.9054 | 100% | 9 ...

证券代码：301130 证券简称：西点药业 公告编号：2023-061 吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理及部分闲置自有资金 进行委托理财到期赎回并继续进行现金管理及委托理财 的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2023 年 1 月 30 日召开第七届董事会第十五次会议、第七届监事会第十三次会议，并于 2023 年 2 月 15 日召开 2023 年第一次临时股东大会审议通过了《关于使用部分闲置募 集资金及自有资金进行现金管理的议案》，同意公司在确保公司募集资金投资项 目建设正常进行和资金安全的前提下，使用额度不超过人民币 2.8 亿元的部分闲 置募集资金（含超募资金）及额度不超过人民币 2.0 亿元自有资金进行现金管理， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可 循环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募 ...

证券代码：301130 证券简称：西点药业 公告编号：2023-060 吉林省西点药业科技发展股份有限公司 关于珠海横琴子公司完成工商登记并取得营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开了第八届董事会第二次会议，审议通过了《关于拟设立全资子公司 的议案》，同意公司拟使用自有资金 2000 万元人民币在广东省珠海市设立全资 子公司西点（珠海横琴）医药科技有限公司（暂定名，最终以市场监督管理部门 核准结果为准，以下简称"西点医药"），并授权公司管理层办理西点医药的设 立登记事宜。具体内容详见公司在巨潮资讯网上披露的《关于拟设立全资子公司 的公告》（公告编号：2023-059）。 近日，公司完成了相关工商登记手续，并取得了横琴粤澳深度合作区商事 服务局颁发的《营业执照》。相关工商登记信息如下： 名称：西点（珠海横琴）医药科技有限公司 统一社会信用代码：91440400MACTLU1H7Y 类型：有限责任公司（自然人投资或控股的法人独资） 注册资本： 20 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[17]. - The net profit attributable to shareholders for the same period was RMB 80 million, up 20% compared to the previous year[17]. - Future guidance estimates a revenue growth of 10-15% for the full year 2023[17]. - The company's operating revenue for the current period is CNY 114,087,002.92, a decrease of 2.18% compared to the same period last year[24]. - Net profit attributable to shareholders of the listed company is CNY 30,323,289.46, an increase of 46.24% year-on-year[24]. - The net profit after deducting non-recurring gains and losses is CNY 14,975,978.33, down 23.98% from the previous year[24]. - The net cash flow from operating activities is CNY 19,803,571.88, a decrease of 42.76% compared to the same period last year[24]. - Basic and diluted earnings per share are both CNY 0.3753, reflecting a growth of 34.08% year-on-year[24]. - Total assets at the end of the reporting period are CNY 1,020,486,301.86, an increase of 0.34% from the end of the previous year[24]. - The net assets attributable to shareholders of the listed company are CNY 962,684,284.91, up 1.84% from the previous year[24]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[17]. - The company plans to launch three new products in the second half of 2023, focusing on innovative drug formulations[17]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach[17]. - The sales strategy includes a combination of agency promotion and self-operated models to expand market share and enhance product influence[42]. - The company has established a comprehensive market sales system, with regional managers overseeing agent qualifications and product promotion[41]. Research and Development - Research and development expenses increased by 12%, totaling RMB 50 million, reflecting a commitment to innovation[17]. - The company employs a collaborative R&D model, enhancing product quality and capacity through self-research and partnerships with leading third-party R&D institutions[38]. - Research and development investment amounted to 3.059 million yuan, a year-on-year increase of 5.62%, accounting for 2.68% of the current operating income[36]. - The company has completed a 24-month long-term stability study for the risperidone orally disintegrating tablets, with results meeting national quality standards[53]. - The company has achieved industrial production of calcium citrate raw materials, obtaining A status registration, which enhances the sales scale of raw materials and integrates raw materials with formulations[53]. Environmental Compliance and Sustainability - The company holds a pollution discharge permit valid from September 8, 2022, to September 7, 2027[121]. - The company has received multiple environmental impact assessments for various projects, including the solid preparation workshop expansion and raw material drug production[121]. - The company reported a total emission of 0.04106 tons of particulate matter from its production line, complying with the emission standard of 20 mg/m3[121]. - The company has implemented measures to ensure compliance with air pollution discharge standards[121]. - The company is focused on reducing hazardous waste emissions and improving environmental compliance[123]. Financial Management and Investments - The company’s investment activities generated a net cash inflow of approximately ¥41.36 million, a significant improvement compared to a net outflow of approximately ¥371.34 million in the previous year[65]. - The company has committed to invest RMB 10,576 million in the comprehensive solid preparation project, with an investment progress of 8.99% as of the reporting period[87]. - The company has ongoing projects with a total investment of 5,301,721.14, primarily funded through self-owned capital[79]. - The company reported a total of 39,093.31 million RMB in fundraising, with 8,615 million RMB allocated for various projects[89]. - The company has a cash management balance of RMB 26,000 million, with RMB 5,671.64 million remaining in the special account for raised funds[85]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[3]. - The company faces significant policy risks due to ongoing medical system reforms, which may increase operational costs and impact business performance if not adapted timely[106]. - Environmental protection pressures are rising, leading to higher compliance costs and potential risks if pollution standards are not met[109]. - Fluctuations in raw material prices, particularly for chemical raw materials and traditional Chinese medicine, could adversely affect the company's gross margin and operational risks[110]. Shareholder and Governance - The company has established a governance structure that includes a board of directors and various committees to ensure effective operation and protect the rights of shareholders and creditors[143]. - The company actively engages with investors and participated in an online performance briefing on May 22, 2023, to enhance communication and transparency[144]. - The company has revised its profit distribution policy to ensure fair returns to shareholders, including specific conditions for cash dividends[144]. - The total number of ordinary shareholders at the end of the reporting period is 9,937[185]. - Zhang Jun holds 24.29% of the shares, totaling 19,627,034 shares[185].

证券代码：301130 证券简称：西点药业 公告编号：2023-058 吉林省西点药业科技发展股份有限公司董事会 关于 2023 年半年度募集资金存放与使用情况的专项 报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意吉林省西点药业科技发展股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕5号）同意注册，吉林省 西点药业科技发展股份有限公司（以下简称"公司"或"本公司"）首次公开发 行人民币普通股（A股）股票2,020.0986万股，每股面值1元，每股发行价格为人 民币22.55元，募集资金总额为人民币45,553.22万元，扣除各类发行费用后实际 募集资金净额为人民币39,093.31万元。 上述募集资金到位情况已经大华会计师事务所（特殊普通合伙）于2022年2 月18日出具的大华验字[2022]000086号《验资报告》验证。 (二) 募集资金使用和结余情况 截至 2023 年 6 月 30 日止，公司首次公开发行募集资金使用情况及余额 具体情 ...

海通证券股份有限公司关于 2023 半年度跟踪报告 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2、督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、募 | 是 | | 集资金管理制度、内控制度、内部审计制度、 | | | 关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 0 次 | | （2）列席公司董事会次数 | 次 1 | | （3）列席公司监事会次数 | 0 次 | | 5、现场检查情况 | | 1 | （1）现场检查次数 | 0 次 | | --- | ...